XML 56 R42.htm IDEA: XBRL DOCUMENT v3.24.1
Goodwill and Intangible Assets (Tables)
12 Months Ended
Nov. 14, 2023
Dec. 29, 2023
Goodwill and Intangible Assets Disclosure [Abstract]    
Schedule of Intangible Assets  
The gross carrying amount and accumulated amortization of intangible assets were comprised of the following at the end of each period:
SuccessorPredecessor
December 29, 2023December 30, 2022
Gross
Carrying
Amount
Accumulated
Amortization
Gross
Carrying
Amount
Accumulated
Amortization
Amortizable:
Completed technology$624.6 $16.2 $3,041.2 $318.7 
Non-Amortizable:
In-process research and development— 121.3 
Finite-lived Intangible Assets Amortization Expense  
Intangible asset amortization expense was as follows:
SuccessorPredecessor
Period from
November 15, 2023
through December 29, 2023
Period from
December 31, 2022
through
November 14, 2023
Period from
June 17, 2022
through
December 30, 2022
Period from
January 1, 2022
through
June 16, 2022
Year Ended December 31, 2021
Amortization expense$16.2 $449.6 $318.7 $281.8 $581.1 
Schedule of Future Amortization Expense, Intangible Assets  
The estimated aggregate amortization expense on intangible assets owned by the Company and being amortized as of December 29, 2023 (Successor) is expected to be as follows:
Fiscal 2024$90.3 
Fiscal 202574.8 
Fiscal 202668.4 
Fiscal 202762.0 
Fiscal 202855.6 
Schedule of Intangible Assets and Goodwill
Intangible assets of the Successor as of the 2023 Effective Date consisted of the following:
Carrying AmountAmortization Method
Amortization Period (in years)
Discount RateSegment
Amortizable completed technology:
Acthar Gel$110.0 Sum of the years digits10.052.3%Specialty Brands
Therakos129.4 Sum of the years digits9.051.5Specialty Brands
Amitiza12.3 Sum of the years digits1.051.5Specialty Brands
INOmax41.3 Sum of the years digits8.051.5Specialty Brands
Terlivaz
68.1 Straight-line5.552.5Specialty Brands
Generics186.7 Straight-line18.014.1Specialty Generics
APAP76.8 Straight-line20.013.5Specialty Generics
$624.6